LONDON, Jan. 11, 2017 /PRNewswire/ -- Use this report
to:
- Evaluate new commercial opportunities in the glycobiology
diagnostics, therapeutics and research tools market.
- Analyze major market participants, including current and future
market trends of the glycobiology industry.
- Analyze the drivers and challenges in each segment of the
glycobiology market.
- Gain information about significant players in the field of
glycobiology industry.
Highlights
- The global market for glycobiology will grow from nearly
$24.6 billion in 2016 to nearly
$50.1 billion by 2021 with a compound
annual growth rate (CAGR) of 15.3% for the period of 2016-2021.
- The therapeutics market is the largest segment of the
glycobiology industry and will grow from $19.0 billion in 2016 to $40.0 billion by 2021, with a CAGR of 16.1%.
- The diagnostics market is expected to increase from $5.5 billion in 2016 to $10.0 billion by 2021, with a CAGR of 12.7%.
Introduction & Scope
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC Research report, Glycobiology: Global Markets for
Diagnostics and Therapeutics, provides an overview of glycans as
novel drugs as therapeutic targets,
glycan-based diagnostics and a detailed analysis of the competitive
environment, including potential new markets for novel products,
biomarkers and drug development. The study includes information
about significant players in this field of study, trends and
challenges and other information affecting the development of the
market for glycobiology.
REASONS FOR DOING THIS STUDY
The importance of carbohydrates in biological processes has long
been underappreciated. Nevertheless, with new tools for
synthesizing, modifying and studying oligosaccharides and
glycoconjugates, the understanding of these biomolecules is rapidly
improving. This knowledge is also yielding promising candidates for
carbohydrate-based diagnostics, drugs and vaccines. Importantly,
the study of such molecules is technically challenging as no
sequencing tool, such as that used in proteomics or genomics, is
available. However, following on from genomics and proteomics,
there is increasing recognition of the importance of
carbohydrate-based molecules in basic cellular processes. The
central role of saccharides in cellular interactions means that
novel oligosaccharides are of value in R&D programs addressing
a wide range of therapeutic areas, including inflammation,
immunity, oncology, neurodegenerative disease, infection and
more.
Because of their essential function in many cellular processes,
carbohydrates are also important biomarkers in diagnostic assay
development. This report will highlight the main segments of the
glycobiology industry and its major market participants, including
current and future market trends. Drivers and challenges in each
segment of this industry will be discussed in detail, with a
forecast from 2016 through 2021.
SCOPE AND FORMAT
This report presents current and important business tools to
evaluate new commercial opportunities in glycobiology diagnostics,
therapeutics and research tools market. The geographic scope of
this study covers companies in the U.S. and worldwide. This market
is complex and consists of number of different segments, each
affected differently by scientific and technological development.
The report identifies the main positive and negative factors in
each segment and forecasts further trends, products and assay
developments.
METHODOLOGY AND INFORMATION SOURCES
The research methodology was mainly qualitative in nature and used
a triangulation approach to increase the credibility and validity
of the data. Initially, a comprehensive and exhaustive search of
the literature on diagnostics, therapeutics and already marketed
research tools products was conducted. These secondary sources
included drug development, science-related journals, textbooks,
press releases, marketing literature, other product/promotional
literature, annual reports, security analyst reports and other
publications. A patent search and analysis was also conducted. In a
second phase, a series of semi-structure interviews were conducted
with company representatives, bench scientist, marketing
representative and other personnel at biotech and pharmaceutical
companies. Other resources included academics, technology and
consulting companies. These were a rich source of data. Subsequent
analysis of the documents and interviews notes was iterative.
INTENDED AUDIENCE
This report is intended for business development professionals,
entrepreneurs and other investment groups in order fully understand
and evaluate properly each segment of the glycobiology market. It
provides a company's corporate development new insight into their
competitor's position and shows new opportunities otherwise
overlooked or less known to the public.
Download the full report:
https://www.reportbuyer.com/product/4186198/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/glycobiology-global-markets-for-diagnostics-and-therapeutics-300389538.html
SOURCE ReportBuyer